COLLEGIUM PHARM INC
SpecialtyCOLLEGIUM PHARM INC is a specialty pharmaceutical company focused on Neurology. Key products include NUCYNTA ER.
COLLEGIUM PHARM INC's Key Drugs
COLLEGIUM PHARM INC's core commercial portfolio centers on NUCYNTA ER, XTAMPZA ER, spanning Neurology — its most strategically important drugs approved in the last 15 years.
COLLEGIUM PHARM INC's Recent FDA Approvals
New NDA/BLA approvals for COLLEGIUM PHARM INC over the last two years — novel drugs only, excluding generics and label supplements.
COLLEGIUM PHARM INC's Therapeutic Areas
COLLEGIUM PHARM INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COLLEGIUM PHARM INC's Top Competitors
COLLEGIUM PHARM INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COLLEGIUM PHARM INC Pipeline Snapshot
Active clinical trials for COLLEGIUM PHARM INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NUCYNTA ER leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2008-11-20
- Latest
- 2026-06-18
- Applications
- 4